The Founder's Guide to

BrightEdge - American Cancer Society

Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.

Explore our founder-friendly guide and choose if you'd like to be connected.
We'll either provide a warm intro or provide you with more suitable alternatives.
Once you're put in touch, we'll provide you with helpful advice. It's 100% free.

Overview

BrightEdge is the innovation and impact investment arm of the American Cancer Society, founded in 2018. It focuses on leveraging ACS's legacy in cancer research to invest in scalable solutions addressing unmet needs in cancer care. The firm operates globally and participates in funding stages from pre-seed to Series A.

Learn More

Frequently Asked Questions

Does BrightEdge lead rounds?

BrightEdge typically participates in funding rounds but does not exclusively lead them. They collaborate with other investors to support early-stage innovations in cancer care.

What is BrightEdge's stance on follow-on investments?

BrightEdge is open to follow-on investments, particularly for companies that demonstrate significant progress and alignment with their mission to improve cancer care.

How large is BrightEdge's current fund?

The specific size of BrightEdge's current fund is not publicly disclosed, but they are actively investing in early-stage companies across various funding rounds.

All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.